FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740809417> ?p ?o ?g. }

• W2740809417 abstract "Background: Castration-resistant prostate cancers that express the constitutively active androgen receptor (AR) variant AR-V7 exhibit significantly reduced progression-free and overall survival in response to the AR targeting agents, enzalutamide (ENZ) and abiraterone. Inhibition of Phosphoinositide-3-Kinase (PIK3CA) or CDK4/6 has been proposed as alternative therapies that directly target the cell cycle pathway in these tumors. However, the combined role of AR plus cell cycle inhibition in this treatment setting has not been established. G1T38 is a potent, selective clinical stage CDK 4/6 inhibitor. Seviteronel (SEVI) is a selective CYP17-lyase and AR inhibitor that blocks the growth of CRPC tumors with clinically relevant AR mutations, including T878A and AR-F876L. The activity of SEVI, ENZ and G1T38, alone or in combination, was evaluated using the 22Rv1 (AR-V7+) CRPC model in vitro and in vivo. Methods: Cellular proliferation (7 days) of 22Rv1 prostate cancer cells treated with SEVI, ENZ, and G1T38 alone or in combination with SEVI or ENZA was assessed by measuring DNA content. Orchiectomized male nu/nu mice bearing 22Rv1 were randomized to receive vehicle, SEVI (150mg/kg/day p.o.), ENZ (30 mg/kg/day p.o.), G1T38 (25-100 mg/kg/day p.o.), or SEVI or ENZ in combination with G1T38. A docetaxel (20 mg/kg weekly i.p.) group was included as a standard of care comparison. Time to progression (X-fold increase in tumor volume) and tumor volume changes were assessed over a 3-7-week dosing period. Blood and tissues were collected for analysis of exposure and pharmacodynamics markers of response. Results: SEVI and G1T38 alone or in combination, significantly reduced the proliferation of 22Rv1 cells in vitro (p Conclusions: SEVI and G1T38 mono- or combination therapy significantly decreased the growth of the AR-V7+ 22Rv1 CPRC model in vitro and in vivo, an activity that distinguishes SEVI from ENZ. Therefore, combining SEVI with a CDK4/6 inhibitor such as G1T38 may be an effective therapy for the treatment of CRPC that is resistant to current standards of care. Citation Format: Suzanne E. Wardell, Alexander P. Yllanes, John D. Norris, James P. Stice, Hannah White, Ronald A. Fleming, Jay C. Strum, William R. Moore, Donald P. McDonnell. Effects of the selective CYP17-lyase and androgen receptor (AR) inhibitor, seviteronel, and the cyclin-dependent kinase (CDK) 4/6 inhibitor, G1T38, on tumor growth in an AR-V7+ castration-resistant prostate cancer (CRPC) xenograft model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1588. doi:10.1158/1538-7445.AM2017-1588" @default.
• W2740809417 created "2017-08-08" @default.
• W2740809417 creator A5012103903 @default.
• W2740809417 creator A5028399634 @default.
• W2740809417 creator A5036776589 @default.
• W2740809417 creator A5037332413 @default.
• W2740809417 creator A5037408779 @default.
• W2740809417 creator A5055459877 @default.
• W2740809417 creator A5062055452 @default.
• W2740809417 creator A5074827379 @default.
• W2740809417 creator A5078598967 @default.
• W2740809417 date "2017-07-01" @default.
• W2740809417 modified "2023-09-26" @default.
• W2740809417 title "Abstract 1588: Effects of the selective CYP17-lyase and androgen receptor (AR) inhibitor, seviteronel, and the cyclin-dependent kinase (CDK) 4/6 inhibitor, G1T38, on tumor growth in an AR-V7+ castration-resistant prostate cancer (CRPC) xenograft model" @default.
• W2740809417 doi "https://doi.org/10.1158/1538-7445.am2017-1588" @default.
• W2740809417 hasPublicationYear "2017" @default.
• W2740809417 type Work @default.
• W2740809417 sameAs 2740809417 @default.
• W2740809417 citedByCount "1" @default.
• W2740809417 countsByYear W27408094172021 @default.
• W2740809417 crossrefType "proceedings-article" @default.
• W2740809417 hasAuthorship W2740809417A5012103903 @default.
• W2740809417 hasAuthorship W2740809417A5028399634 @default.
• W2740809417 hasAuthorship W2740809417A5036776589 @default.
• W2740809417 hasAuthorship W2740809417A5037332413 @default.
• W2740809417 hasAuthorship W2740809417A5037408779 @default.
• W2740809417 hasAuthorship W2740809417A5055459877 @default.
• W2740809417 hasAuthorship W2740809417A5062055452 @default.
• W2740809417 hasAuthorship W2740809417A5074827379 @default.
• W2740809417 hasAuthorship W2740809417A5078598967 @default.
• W2740809417 hasConcept C121608353 @default.
• W2740809417 hasConcept C124320809 @default.
• W2740809417 hasConcept C126322002 @default.
• W2740809417 hasConcept C184235292 @default.
• W2740809417 hasConcept C185592680 @default.
• W2740809417 hasConcept C2775930923 @default.
• W2740809417 hasConcept C2776551883 @default.
• W2740809417 hasConcept C2778298596 @default.
• W2740809417 hasConcept C2779707156 @default.
• W2740809417 hasConcept C2779744173 @default.
• W2740809417 hasConcept C2780192828 @default.
• W2740809417 hasConcept C2781190966 @default.
• W2740809417 hasConcept C29537977 @default.
• W2740809417 hasConcept C502942594 @default.
• W2740809417 hasConcept C530470458 @default.
• W2740809417 hasConcept C55493867 @default.
• W2740809417 hasConcept C61367390 @default.
• W2740809417 hasConcept C62112901 @default.
• W2740809417 hasConcept C71924100 @default.
• W2740809417 hasConcept C98274493 @default.
• W2740809417 hasConceptScore W2740809417C121608353 @default.
• W2740809417 hasConceptScore W2740809417C124320809 @default.
• W2740809417 hasConceptScore W2740809417C126322002 @default.
• W2740809417 hasConceptScore W2740809417C184235292 @default.
• W2740809417 hasConceptScore W2740809417C185592680 @default.
• W2740809417 hasConceptScore W2740809417C2775930923 @default.
• W2740809417 hasConceptScore W2740809417C2776551883 @default.
• W2740809417 hasConceptScore W2740809417C2778298596 @default.
• W2740809417 hasConceptScore W2740809417C2779707156 @default.
• W2740809417 hasConceptScore W2740809417C2779744173 @default.
• W2740809417 hasConceptScore W2740809417C2780192828 @default.
• W2740809417 hasConceptScore W2740809417C2781190966 @default.
• W2740809417 hasConceptScore W2740809417C29537977 @default.
• W2740809417 hasConceptScore W2740809417C502942594 @default.
• W2740809417 hasConceptScore W2740809417C530470458 @default.
• W2740809417 hasConceptScore W2740809417C55493867 @default.
• W2740809417 hasConceptScore W2740809417C61367390 @default.
• W2740809417 hasConceptScore W2740809417C62112901 @default.
• W2740809417 hasConceptScore W2740809417C71924100 @default.
• W2740809417 hasConceptScore W2740809417C98274493 @default.
• W2740809417 hasLocation W27408094171 @default.
• W2740809417 hasOpenAccess W2740809417 @default.
• W2740809417 hasPrimaryLocation W27408094171 @default.
• W2740809417 hasRelatedWork W1586395695 @default.
• W2740809417 hasRelatedWork W1980250856 @default.
• W2740809417 hasRelatedWork W2040076798 @default.
• W2740809417 hasRelatedWork W2078860063 @default.
• W2740809417 hasRelatedWork W2078892287 @default.
• W2740809417 hasRelatedWork W2148047944 @default.
• W2740809417 hasRelatedWork W2325428616 @default.
• W2740809417 hasRelatedWork W2484658642 @default.
• W2740809417 hasRelatedWork W2505717779 @default.
• W2740809417 hasRelatedWork W2563015194 @default.
• W2740809417 hasRelatedWork W2594336705 @default.
• W2740809417 hasRelatedWork W2740471317 @default.
• W2740809417 hasRelatedWork W2810635684 @default.
• W2740809417 hasRelatedWork W2886934564 @default.
• W2740809417 hasRelatedWork W2891971316 @default.
• W2740809417 hasRelatedWork W2944097703 @default.
• W2740809417 hasRelatedWork W2955362334 @default.
• W2740809417 hasRelatedWork W2991168666 @default.
• W2740809417 hasRelatedWork W3008253605 @default.
• W2740809417 hasRelatedWork W3028779753 @default.
• W2740809417 isParatext "false" @default.
• W2740809417 isRetracted "false" @default.
• W2740809417 magId "2740809417" @default.
• W2740809417 workType "article" @default.